These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 33454550)
1. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550 [TBL] [Abstract][Full Text] [Related]
2. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. Lin X; Lu X; Luo G; Xiang H Eur J Med Chem; 2020 Jan; 186():111876. PubMed ID: 31761384 [TBL] [Abstract][Full Text] [Related]
3. Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. Wu X; Meng Y; Liu L; Gong G; Zhang H; Hou Y; Liu C; Wu D; Qin M Bioorg Med Chem; 2021 Mar; 33():116038. PubMed ID: 33517226 [TBL] [Abstract][Full Text] [Related]
4. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy. Chen R; Yuan D; Ma J Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447 [TBL] [Abstract][Full Text] [Related]
5. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005 [TBL] [Abstract][Full Text] [Related]
6. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors? Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193 [TBL] [Abstract][Full Text] [Related]
7. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy. Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417 [TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules. Geng Q; Jiao P; Jin P; Su G; Dong J; Yan B Curr Pharm Des; 2018 Feb; 23(39):6033-6041. PubMed ID: 28982322 [TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Yang Y; Wang K; Chen H; Feng Z Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783 [TBL] [Abstract][Full Text] [Related]
10. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. Yang J; Hu L Med Res Rev; 2019 Jan; 39(1):265-301. PubMed ID: 30215856 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and Wu T; Cheng H; Sima L; Wang Z; Ouyang W; Wang J; Hou Y; Zhao D; Liao W; Hu C J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2353711. PubMed ID: 38887057 [TBL] [Abstract][Full Text] [Related]
12. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy? Chen T; Li Q; Liu Z; Chen Y; Feng F; Sun H Eur J Med Chem; 2019 Jan; 161():378-398. PubMed ID: 30384043 [TBL] [Abstract][Full Text] [Related]
13. C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction. Klimek J; Kruc O; Ceklarz J; Kamińska B; Musielak B; van der Straat R; Dӧmling A; Holak TA; Muszak D; Kalinowska-Tłuścik J; Skalniak Ł; Surmiak E Molecules; 2024 Jun; 29(11):. PubMed ID: 38893521 [TBL] [Abstract][Full Text] [Related]
14. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH Front Immunol; 2021; 12():654463. PubMed ID: 34054817 [TBL] [Abstract][Full Text] [Related]
15. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA Molecules; 2019 May; 24(11):. PubMed ID: 31151293 [TBL] [Abstract][Full Text] [Related]
16. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906 [TBL] [Abstract][Full Text] [Related]
17. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy. Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579 [TBL] [Abstract][Full Text] [Related]
19. Identification of the FDA-Approved Drug Pyrvinium as a Small-Molecule Inhibitor of the PD-1/PD-L1 Interaction. Fattakhova E; Hofer J; DiFlumeri J; Cobb M; Dando T; Romisher Z; Wellington J; Oravic M; Radnoff M; Patil SP ChemMedChem; 2021 Sep; 16(18):2769-2774. PubMed ID: 34117723 [TBL] [Abstract][Full Text] [Related]
20. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Ai L; Chen J; Yan H; He Q; Luo P; Xu Z; Yang X Drug Des Devel Ther; 2020; 14():3625-3649. PubMed ID: 32982171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]